Ocular Therapeutix (OCUL) News Today $8.83 +0.31 (+3.64%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ocular Therapeutix Reports Q3 2024 Financial ResultsNovember 17, 2024 | markets.businessinsider.comOcular Therapeutix (OCUL) Gets a Buy from ScotiabankNovember 16, 2024 | markets.businessinsider.comGSA Capital Partners LLP Purchases New Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)GSA Capital Partners LLP acquired a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 126,681 shares of the biopharmaceutical company'sNovember 16, 2024 | marketbeat.com**Ocular Therapeutix, Inc. Announces Third Quarter 2024 Financial Results and Business Highlights** **November 16, 2024 | americanbankingnews.comOcular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...November 16, 2024 | finance.yahoo.comOcular Therapeutix: Strategic Progress and Promising Pipeline Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comOcular Therapeutix price target raised to $15 from $14 at H.C. WainwrightNovember 16, 2024 | markets.businessinsider.comHC Wainwright Raises Ocular Therapeutix (NASDAQ:OCUL) Price Target to $15.00HC Wainwright upped their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday.November 15, 2024 | marketbeat.comQ3 2024 Ocular Therapeutix Inc Earnings CallNovember 15, 2024 | uk.finance.yahoo.comA Peek at Ocular Therapeutix's Future EarningsNovember 14, 2024 | benzinga.comOcular Therapeutix’s Clinical Progress and Strategic Trials Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comOcular Therapeutix™ Reports Third Quarter 2024 Results and Business HighlightsNovember 14, 2024 | finance.yahoo.comOcular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIVNovember 13, 2024 | globenewswire.comOcular Therapeutix, Inc.: Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business OfficerNovember 13, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business OfficerNovember 13, 2024 | finanznachrichten.deOcular Therapeutix appoints Saroj as Chief Business OfficerNovember 13, 2024 | markets.businessinsider.comOcular Therapeutix appoints Saroj as Chief Business OfficerNovember 13, 2024 | markets.businessinsider.comOcular Therapeutix (OCUL) Set to Announce Quarterly Earnings on ThursdayOcular Therapeutix (NASDAQ:OCUL) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comOcular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024November 6, 2024 | globenewswire.comRosalind Advisors Inc. Grows Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Rosalind Advisors Inc. increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 18.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 885,000 shares of the biopharmaceutical cNovember 6, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating oNovember 2, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Hits New 12-Month High - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week High - Here's WhyOctober 28, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Sees Large Decrease in Short InterestOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 13,260,000 shares, a decline of 18.1% from the September 30th total of 16,190,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is currently 11.4 days.October 28, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $24.58 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,825,756 shares of the biopharmaceutical company'sOctober 26, 2024 | marketbeat.comPiper Sandler Remains a Buy on Ocular Therapeutix (OCUL)October 22, 2024 | markets.businessinsider.comSG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL)SG Americas Securities LLC purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 45,187 shares of the biopharmaceutical company's stock,October 18, 2024 | marketbeat.comOptimistic Buy Rating for Ocular Therapeutix Amid Accelerated SOL-1 Study ProgressOctober 18, 2024 | markets.businessinsider.comScotiabank Initiates Coverage of Ocular Therapeutix (OCUL) with Sector Outperform RecommendationOctober 17, 2024 | msn.comOcular Therapeutix (NASDAQ:OCUL) Reaches New 12-Month High - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Sets New 12-Month High - Here's What HappenedOctober 17, 2024 | marketbeat.comBuy Rating on Ocular Therapeutix: Accelerated Phase 3 Trial Enrollment and Promising 2025 OutlookOctober 16, 2024 | markets.businessinsider.comOcular Therapeutix’s Promising Clinical Advancements and Strategic Trials Drive Buy RatingOctober 16, 2024 | markets.businessinsider.comOcular Therapeutix (NASDAQ:OCUL) Trading Up 4.9% - Still a Buy?Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 4.9% - What's Next?October 16, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $14.00 price target on shares of Ocular Therapeutix in a report on Wednesday.October 16, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Coverage Initiated at ScotiabankScotiabank started coverage on shares of Ocular Therapeutix in a research note on Wednesday. They issued a "sector outperform" rating for the company.October 16, 2024 | marketbeat.comOcular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMDOctober 15, 2024 | globenewswire.comOcular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To InvestorsOctober 11, 2024 | seekingalpha.comAmendment to 2019 Inducement Stock Incentive Plan Boosts Ocular Therapeutix’s SharesOcular Therapeutix, Inc. made a significant change to its 2019 Inducement Stock Incentive Plan, as disclosed in a recent filing with the Securities and Exchange Commission on October 4, 2024. The company's board of directors approved an amendment to increase the total number of shares available undeOctober 10, 2024 | marketbeat.comOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 9, 2024 | globenewswire.comOcular Therapeutix™ to Present at October Ophthalmology MeetingsOctober 9, 2024 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buyOctober 8, 2024 | marketbeat.comMarshall Wace LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Marshall Wace LLP purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 429,592 shares of the biopharmaceutical company's stock, valued aOctober 4, 2024 | marketbeat.comOcular Therapeutix (OCUL) Gets a Buy from Piper SandlerOctober 2, 2024 | markets.businessinsider.comNantahala Capital Management LLC Buys Shares of 1,000,000 Ocular Therapeutix, Inc. (NASDAQ:OCUL)Nantahala Capital Management LLC purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,000,000 shares of the biopharmaceutical company's stock, valued aOctober 1, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases Shares of 2,706,663 Ocular Therapeutix, Inc. (NASDAQ:OCUL)Point72 Asset Management L.P. purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,706,663 sharSeptember 30, 2024 | marketbeat.comPolish c.banker Duda says discussion about rate cuts may start in MarchSeptember 25, 2024 | ca.finance.yahoo.comOcular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024September 25, 2024 | globenewswire.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Logos Global Management LPLogos Global Management LP decreased its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 11.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,150,000 shares of the biopharmaceutical company's stock after seSeptember 24, 2024 | marketbeat.comTri Locum Partners LP Makes New $3.52 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Tri Locum Partners LP purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 514,642 shares oSeptember 23, 2024 | marketbeat.comRhumbline Advisers Raises Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Rhumbline Advisers lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 39.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 211,301 shares of the biopharmaceuticaSeptember 22, 2024 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)September 20, 2024 | markets.businessinsider.com Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. OCUL Media Mentions By Week OCUL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼0.550.49▲Average Medical News Sentiment OCUL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼75▲OCUL Articles Average Week Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARQT News Today INVA News Today KNSA News Today PLRX News Today SUPN News Today PHAT News Today TBPH News Today KPTI News Today CRNX News Today KRYS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUL Stock Alerts